SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Stopped early · Phase 1
Conditions studied: Small Cell Lung Cancer
In brief
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.
Key facts
- Study ID
- NCT02500914
- Run by
- Stemcentrx
- People needed
- 35
- Starts
- 2015-06-01
- Expected to finish
- 2018-08-23
- Last updated by the study team
- 2018-10-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
- Evidence of progressive disease during or following no more than 2 prior chemotherapy regimens
- Measurable disease as defined by RECIST
- ECOG performance status of 0 or 1
- Adequate hematological and organ function as confirmed by laboratory values
- Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of SC-002
You may not qualify if…
- Active central nervous system metastases
- Uncontrolled cardiac disease
- Positive serology for hepatitis B or hepatitis C or known HIV infection
- Presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results
Where it is running
- Study site — Ann Arbor, Michigan, United States
- Study site — St Louis, Missouri, United States
- Study site — New York, New York, United States
- Study site — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.